Abstract
In recent years, great progress has been made in treatment of patients with HCV infection with direct-acting antiviral agents(DAAs). Up to now, twelve kinds of oral DAAs and three kinds of combination regimens have been approved by the U. S. Food and Drug Administration and European Medicines Agency to treat chronic HCV infection. This article reviews the research progress of DAAs in treatment of hepatitis C, including the name of DAAs, drug targets, therapy regimen, clinical efficacy and adverse effects. Key words: Hepatitis C; Direct-acting antiviral agents; Sustained viral response
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
